Residual inflammatory risk after contemporary lipid lowering therapy
Residual inflammatory risk after contemporary lipid lowering therapy
About this item
Full title
Author / Creator
Publisher
England: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
England: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Abstract
Background
Recently, there has been an increasing interest in targeting inflammation to reduce major adverse cardiovascular events (MACE) in patients with cardiovascular risk. Statins, PCSK9 inhibitors, and ezetimibe have been shown to reduce MACE owing to reduction in low-density lipoproteins cholesterol (LDL-c). Herein, we investig...
Alternative Titles
Full title
Residual inflammatory risk after contemporary lipid lowering therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7850089
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7850089
Other Identifiers
ISSN
2058-5225,2058-1742
E-ISSN
2058-1742
DOI
10.1093/ehjqcco/qcz055
